FilingReader Intelligence

Bloomage Biotechnology sees revenue dip, reassures on long-term growth

June 30, 2025 at 05:15 PM UTCBy FilingReader AI

** Bloomage Biotechnology Corporation (SSE:688363) reported a 11.61% dip in revenue to CNY 5.37 billion for 2024. While raw material and medical end businesses saw positive growth, a strategic shift in the company's skin care line was a primary factor in the decline. Net profit attributable to shareholders fell 70.59% to CNY 174 million due to these changes.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Bloomage Biotechnology Corporation publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →